BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 16643716)

  • 21. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age.
    Seeman E; Boonen S; Borgström F; Vellas B; Aquino JP; Semler J; Benhamou CL; Kaufman JM; Reginster JY
    Bone; 2010 Apr; 46(4):1038-42. PubMed ID: 20026265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New anabolic therapies in osteoporosis.
    Rubin MR; Bilezikian JP
    Curr Opin Rheumatol; 2002 Jul; 14(4):433-40. PubMed ID: 12118181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of osteoporosis: role of bone-forming agents.
    Reginster JY; Halkin V; Henrotin Y; Gosset C
    Osteoporos Int; 1999; 9 Suppl 2():S91-6. PubMed ID: 10525731
    [No Abstract]   [Full Text] [Related]  

  • 24. New anabolic agents in the treatment of osteoporosis.
    Hough S
    S Afr Med J; 2003 Oct; 93(10):754-6. PubMed ID: 14652963
    [No Abstract]   [Full Text] [Related]  

  • 25. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
    O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window.
    Bilezikian JP
    Curr Osteoporos Rep; 2008 Mar; 6(1):24-30. PubMed ID: 18430397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mixed-treatment comparison of anabolic (teriparatide and PTH 1-84) therapies in women with severe osteoporosis.
    Migliore A; Broccoli S; Massafra U; Bizzi E; Frediani B
    Curr Med Res Opin; 2012 Mar; 28(3):467-73. PubMed ID: 22256908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Full length parathyroid hormone, PTH(1-84), for the treatment of severe osteoporosis in postmenopausal women.
    Adami S
    Curr Med Res Opin; 2008 Nov; 24(11):3259-74. PubMed ID: 18940041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Up-to-date treatments for osteoporosis].
    Bors K
    Orv Hetil; 2006 Feb; 147(7):301-6. PubMed ID: 17489157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuous broad protection against osteoporotic fractures with strontium ranelate.
    Ferrari S
    Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv20-4. PubMed ID: 19783590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New anabolic therapies in osteoporosis.
    Rubin MR; Bilezikian JP
    Endocrinol Metab Clin North Am; 2003 Mar; 32(1):285-307. PubMed ID: 12699304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis.
    Adami S
    Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Indications to teriparatide treatment in patients with osteoporosis.
    Rizzoli R; Kraenzlin M; Krieg MA; Mellinghoff HU; Lamy O; Lippuner K
    Swiss Med Wkly; 2011; 141():w13297. PubMed ID: 22057669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strontium ranelate in the prevention of osteoporotic fractures.
    Reginster JY; Malaise O; Neuprez A; Bruyere O
    Int J Clin Pract; 2007 Feb; 61(2):324-8. PubMed ID: 17263720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.
    Lindsay R; Nieves J; Formica C; Henneman E; Woelfert L; Shen V; Dempster D; Cosman F
    Lancet; 1997 Aug; 350(9077):550-5. PubMed ID: 9284777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New developments in the treatment of osteoporosis.
    Eriksen EF; Halse J; Moen MH
    Acta Obstet Gynecol Scand; 2013 Jun; 92(6):620-36. PubMed ID: 22646526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis.
    Chew CK; Clarke BL
    Maturitas; 2017 Mar; 97():53-60. PubMed ID: 28159062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.
    Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Ballaouri I; Efstathiadou Z; Kita M; Avramidis A
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):522-6. PubMed ID: 18625000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling.
    Riggs BL; Parfitt AM
    J Bone Miner Res; 2005 Feb; 20(2):177-84. PubMed ID: 15647810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strontium ranelate--a promising therapeutic principle in osteoporosis.
    Boivin G; Doublier A; Farlay D
    J Trace Elem Med Biol; 2012 Jun; 26(2-3):153-6. PubMed ID: 22565017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.